1. Academic Validation
  2. Patient-Derived Melanoma Immune-Tumoroids as a Platform for Precise High throughput Drug Screening

Patient-Derived Melanoma Immune-Tumoroids as a Platform for Precise High throughput Drug Screening

  • Adv Sci (Weinh). 2024 Oct 30:e2408707. doi: 10.1002/advs.202408707.
Juliana Viegas 1 Sofia Costa 1 Sofia Dias 1 2 Catarina Leite Pereira 1 2 Bruno Sarmento 1 2 3
Affiliations

Affiliations

  • 1 i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal.
  • 2 INEB-Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal.
  • 3 IUCS-CESPU-Instituto Universitário de Ciências da Saúde, Rua Central de Gandra 1317, Gandra, 4585-116, Portugal.
Abstract

In vitro models are crucial in Cancer research, but they must truthfully mimic in vivo tumors for clinical relevance. The development of unprecedent melanoma quadruple multicellular tumoroids (MCTs) is proposed comprising tumor cells, keratinocytes, fibroblasts, and monocytes that replicate tumor architecture, tumor microenvironment, and secretome behavior. These MCTs of 300 µm in diameter secreted keratin and collagen, showing complexity proportional to their cell combinations. Further, closely resembled in vivo tumors in terms of cells organization, growth, progression, and immune behavior. Drug screening using these MCTs demonstrated their potential as patient-derived platforms for precision medicine. These findings highlight the true value of MCTs for studying melanoma biology and testing therapeutic interventions with greater precision and relevance to human disease.

Keywords

3D models; in vitro model; multicellular spheroids; patient‐derived; skin cancer.

Figures
Products